KẾT QUẢ ĐIỀU TRỊ BƯỚC SAU UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN DI CĂN XA BẰNG PHÁC ĐỒ ATEZOLIZUMAB ĐƠN TRỊ

Abstract

Aims: The results of Atezolizumab mono therapy in advanced- staged on non-small cell lung cancer. Material and Methods: From January 2019 to June 2022, atezolizumab monotherapy was used to 45 NSCLC patients at K Hospital and the Oncology & Nuclear Medicine Center of Bach Mai Hospital. Patients' clinical symptoms, laboratory results before and after treatment, a regimen's success assessment, and unexpected effects were noted. Results: Disease control rate was 64.4%, and 35.6% of patients taken steps. The response rate was 24.4%. The median progression free survival was 3.1 (95% CI: 2.1-4.7) months. Overall median survival was 9.5 months (95% CI: 8.2-14.5). No serious adverse effect were recorded. Conclusion: result of atezolizumab mono-therapy in advanced- stage non-small cell lung cancer show high response rate, improve pregresstion free survival and overall survival.